Bhagavan, Chiranth http://orcid.org/0000-0002-7983-4280
Kung, Stacey
Doppen, Marjan
John, Mary
Vakalalabure, Iva
Oldfield, Karen
Braithwaite, Irene
Newton-Howes, Giles
Funding for this research was provided by:
Health Research Council of New Zealand (18/1002, 20/057)
Article History
Accepted: 1 November 2020
First Online: 26 November 2020
Declarations
:
: The Medical Research Institute of New Zealand is supported by the Health Research Council of New Zealand (HRC) (Grant nos. 18/1002, 20/057) by way of an independent research organisation grant, and Dr. Karen Oldfield is supported by the HRC through a clinical training fellow grant. No other sources of funding were used to conduct this study or prepare this manuscript.
: Dr. Irene Braithwaite and Dr. Karen Oldfield have undertaken unrelated consultant work for RuaBio, ZHM, Whakaora Pharma and Helius Therapeutics. Dr. Irene Braithwaite, Dr. Karen Oldfield and Dr. Giles Newtown-Howes are members of the Medical Cannabis Research Collaborative. Dr. Giles Newton-Howes sits on the New Zealand Pharmacology and Therapeutics Advisory Committee and the international advisory board for The Australian Centre for Cannabinoid Clinical and Research Excellence. Chiranth Bhagavan, Stacey Kung, Marjan Doppen, Mary John and Iva Vakalalabure have no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Protocol development: IV, MJ, GNH, IB. Literature search: IV, MJ. Title and abstract review: all authors. Interpretation of findings: all authors. Draft manuscript: CB, MD, SK. Final revision of manuscript: all authors. Approval for publication: all authors. Supervision: IB, GNH.